The role of oxidative stress and NF-κB activation in late diabetic complications

BioFactors

Volumn 10, Issue 2-3, 1999, Pages 157-167

  Mohamed, Abdel Khalek ^a   Bierhaus, Angelika ^a   Schiekofer, Stephan ^a   Tritschler, Hans ^b   Ziegler, Reinhard ^a   Nawroth, Peter P ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ASTA Medica   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE;

CELL FUNCTION; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DIABETES MELLITUS; EXTRACELLULAR MATRIX; GENETIC REGULATION; GLOMERULUS BASEMENT MEMBRANE; GLYCATION; HYPERGLYCEMIA; LIGAND BINDING; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR BINDING; TISSUE INJURY; TRANSCRIPTION REGULATION;

EID: 0032720953     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520100211     Document Type: Conference Paper

References (76)

1. M. Abel, U. Ritthaler, Y. Zhang, Y. Deng, A.-M. Schmidt, J. Greten, T. Sernau, P. Wahl, K. Andrassy, E. Ritz, R. Waldherr, D.M. Stern and P.P. Nawroth, Expression of receptors for advanced glycosylated end-products in renal disease, Nephrol. Dial. Transplant. 10 (1995), 1662-1667.
2. P.A. Baeuerle and D. Baltimore, NF-κB: ten years after, Cell 87 (1996), 13-20.
3. P.J. Barnes and M. Karin, Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases, New Engl. J. Med. 336 (1997), 1066-1071.
4. P.J. Beisswenger, Z. Makita, T.J. Curphey, L.L. Moore, S. Jean, T. Brinck-Johnsen, R. Bucala and H. Vlassara, Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes, Diabetes 44 (1995), 824-829.
5. A. Bierhaus, E. Ritz and P.P. Nawroth, Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease, Nephrol. Dial. Transplant. 11(Suppl. 5) (1996), 87-90.
6. A. Bierhaus, S. Chevion, M. Chevion, P. Quehenberger, M. Hofmann, T. Illmer, T. Luther, E. Berentshtein, H. Tritschler, M. Müller, P. Wahl, R. Ziegler and P.P. Nawroth, Advanced glycation endproducts (AGEs) induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells, Diabetes 46 (1997), 1481-1490.
7. Bierhaus A, T. Illmer, M. Kasper, T. Luther, P. Quehenberger, H. Tritschler, P. Wahl, R. Ziegler, M. Müller and P.P. Nawroth, Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE, Circulation 96 (1997), 2262-2271.
8. A. Bierhaus, M.A. Hofmann, R. Ziegler and P.P. Nawroth, The AGE/RAGE pathway in vascular disease and diabetes mellitus. Part I. The AGE-concept, Cardiovascular Res. 37 (1998), 586-600.
9. A. Bierhaus, R. Ziegler and P.P. Nawroth, Molecular mechanisms of diabetic angiopathy - clues for innovative therapeutic interventions, Horm. Res. 50(Suppl. 1) (1998), 1-5.
10. A. Bierhaus, M. Kanits, H. Trischler, R. Ziegler and P.P. Nawroth, A new pathway of perpetuated NF-κB activation potentially relevant in diabetes mellitus, Exp. Clin. Endocrinal Diabetes 106 (1998), 20 (abstract).
11. R. Bucala, Z. Makita, G. Vega, S. Grundy, T. Koschinsky, A. Cerami and H. Vlassara, Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency, Proc. Natl. Acad. Sci. USA 91 (1994), 9441-9445.
12. N.E. Cameron, M.A. Cotter, K. Dines and A. Love, Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats, Diabetologia 35 (1992), 946-950.
13. S. Chevion, M. Hofmann, R. Ziegler, M. Chevion and P.P. Nawroth, The antioxidant properties of thioctic acid: characterization by cyclic voltametry, Biochem. Mol. Biol. Int. 41 (1997), 317-327.
14. T. Collins, Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion, Lab. Invest. 68 (1993), 499-508.
15. R. de-Martin, B. Vanhove, Q. Cheng, E. Hofer, V. Csizmadia, H. Winkler and F.H. Bach, Cytokine-inducible expression in endothelial cells of an I kappa B alpha-like gene is regulated by NF kappa B, EMBO J. 12 (1993), 2773-2779.
16. T.P. Devasagayam, M. Subramanian, D.S. Pradhan and H. Sies, Prevention of singlet oxygen-induced DNA damage by lipoate, Chem. Biol. Interact. 86 (1993), 79-92.
17. C. Esposito, H. Gerlach, J. Brett, D. Stern and H. Vlassara, Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties, J. Exp. Med. 170 (1989), 1387-1407.
18. E. Fenner and G.L. King, Vascular dysfunction in diabetes mellitus. Lancet 350(Suppl. 1) (1997), 9-13.
19. L. Flohe, R. Brigelius-Flohe, C. Saliou, M.G. Traber and L. Packer, Redox regulation of NF-kappa B activation, Free Radic. Biol. Med. 22 (1997), 1115-1126.
20. M.X. Fu, J.R. Requena, A.J. Jenkins, T.J. Lyons, J.W. Baynes and S.R. Thorpe, The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions, J. Biol. Chem. 271 (1996), 9982-9986.
21. A. Ghiselli, O. Laurenti, G. De-Mattia, G. Maiani and A. Ferro-Luzzi, Salicylate hydroxylation as an early marker of in vivo oxidative stress in diabetic patients, Free Radic. Biol. Med. 13 (1992), 621-626.
22. D. Giugliano, A. Ceriello and G. Paolisso, Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress? Metabolism 44 (1995), 363-368.
23. N.K. Gopaul, E.E. Anggard, A.I. Mallet, D.J. Betteridge, S.P. Wolff and J. Nourooz-Zadeh, Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus, FEBS Lett. 368 (1995), 225-229.
24. D.V. Godin, S.A. Wohaieb, M.E. Garnett and A.D. Goumeniouk, Antioxidant enzyme alterations in experimental and clinical diabetes, Mol. Cell Biochem. 84 (1988), 223-231.
25. A. Griesmacher, M. Kinderhauser, S. Andert, W. Schreiner, C. Toma, P. Knoebl, P. Pietschmann and R. Prager, Enhanced serum levels of TBARS in diabetes mellitus, Am. J. Med. 98 (1995), 469-475.
26. A. Gugliucci and M. Bendayan, Histones from diabetic rats contain increased levels of advanced glycation end products, Biochem. Biophys. Res. Commun. 212 (1995), 56-62.
27. A. Gugliucci and M. Bendayan, Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry, J. Histochem. Cytochem. 43 (1995), 591-600.
28. B. Halliwell, The role of oxygen radicals in human disease, with particular reference to the vascular system, Haemostasis 23(Suppl. 1) (1993), 118-126.
29. H.P. Hammes, S. Martin, K. Federlin, K. Geisen and M. Brownlee, Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy, Proc. Natl. Acad. Sci. USA 28 (1991), 11 555-11 558.
30. M.A. Hofmann, S. Schiekofer, M. Kanitz, M.S. Klevesath, M. Joswig, V. Lee, M. Morcos, H. Tritschler, R. Ziegler, P. Wahl, A. Bierhaus and P.P. Nawroth, Insufficient glycemic control increases NF-κB binding activity in peripheral blood mononuclear cells isolated from patients with diabetes mellitus, Diabetes Care 21 (1998), 1310-1316.
31. M.A. Hofmann, S. Schiekofer, M.S. Klevesath, B. Isermann, M. Kanitz, M. Henkels, M. Joswig, A. Treusch, M. Morcos, T. Weiss, V. Borcea, A.K.M. Abdel Khalek, J. Amiral, H. Tritschler, E. Ritz, P. Wahl, R. Ziegler A. Bierhaus and P.P. Nawroth, Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrate increased activation of the oxidative-stress sensitive transcription factor NF-κB, Diabetologia 42 (1999), 222-232.
32. K. Horie, T. Miyata, K. Maeda, S. Miyata, S. Sugiyama, H. Sakai, C.Y. Strihou, V.M. Monnier and J.L. Witztum, Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy, J. Clin. Invest. 100 (1997), 2995-3004.
33. D.R. Johnson, I. Douglas, A. Jahnke, S. Ghosh and J.S. Pober, A sustained reduction in IkappaB-beta may contribute to persistent NF-kappaB activation in human endothelial cells, J. Biol. Chem. 271 (1996), 16 317-16 322.
34. J. Li and A.M. Schmidt, Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products, J. Biol. Chem. 272 (1997), 16498-16 506.
35. V.E. Kagan, A. Shvedova, E. Serbinova et al., Dihydrolipoic acid - a universal antioxidant in the membrane and the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals, Biochem. Pharmacol. 44 (1992), 1637-1649.
36. G.L. King and M. Brownlee, The cellular and molecular mechanisms of diabetic complications, Endocrin. and Metabol. 25 (1996), 255-270.
37. Z. Makita, S. Radoff, E.J. Rayfield, Z. Yang, E. Skolnik, V. Delaney, E.A. Friedman, A. Cerami and H. Vlassara, Advanced glycosylation end products in patients with diabetic nephropathy, New Engl. J. Med. 325 (1991), 836-842.
38. Z. Makita, H. Vlassara, E. Rayfield, K. Cartwright, E. Friedman, R. Rodby, A. Cerami and R. Bucala, Hemoglobin-AGE: a circulating marker of advanced glycosylation, Science 258 (1992), 651-653.
39. S.R. Maxwell, H. Thomason, D. Sandler, C. Leguen, M.A. Baxter, G.H. Thorpe, A.F. Jones and A.H. Barnett, Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus, Eur. J. Clin. Invest. 27 (1997), 484-490.
40. T. Mitsuhashi, H. Nakayama, T. Itoh, S. Kuwajima, S. Aoki, T. Atsumi and T. Koike, Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat, Diabetes 42 (1993), 826-832.
41. T. Murata, R. Nagai, T. Ishibashi, H. Inomuta, K. Ikeda and S. Horiuchi, The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas, Diabetologia 40 (1997), 764-769.
42. T. Nishino, Y. Horii, H. Shiiki et al., Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy, Hum. Pathol. 26 (1995), 308-313.
43. G. Noberasco, P. Odetti, D. Boeri, M. Maiello and L. Adezati, Malondialdehyde (MDA) levels in diabetic subjects. Relationsship with blood glucose and glycosylated hemoglobin, Biomed. Pharmacother. 45 (1991), 193-196.
44. J. Nourooz-Zadeh, J. Tajaddini Sarmadi, S. McCarthy, D.J. Betteridge and S.P. Wolff, Elevated levels of authentic plasma hydroperoxides in NIDDM, Diabetes 44 (1995), 1054-1058.
45. J. Nourooz-Zadeh, A. Rahimi, J. Tajaddini-Sarmadi et al., Relationships between plasma measures of oxidative stress and metabolic control in NIDDM, Diabetologia 40 (1997), 647-653.
46. L. Packer, E.H. Witt and H.J. Tritschler, alpha-Lipoic acid as a biological antioxidant, Free Radic. Biol. Med. 19 (1995), 227-250.
47. K.T. Preissner, S.M. Kanse and H.P. Hammes, Integrin chatter and vascular function in diabetic retinopathy, Horm. Metab. Res. 29 (1997), 643-645.
48. U. Ritthaler, Y. Deng, Y. Zhang, H. Greten, M. Abel, B. Sido, J. Allenberg, G. Otto, H. Roth, A. Bierhaus, R. Ziegler, A.M. Schmidt, R. Waldherr, P. Wahl, D.M. Stern and P.P. Nawroth, Endothelial cell expression of the receptor for advanced glycation end products (RAGE) in peripheral occlusive vascular disease, Am. J. Pathol. 146, 688-694, 18.
49. S. Roy, C.K. Sen, H.J. Tritschler and L. Packer, Modulation of cellular reducing equivalent homeostasis by alpha-lipoic acid. Mechanisms and implications for diabetes and ischemic injury, Biochem. Pharmacol. 53 (1997), 393-399.
50. J.T. Salonen, K. Nyssonen, T.P. Tuomainen, P.H. Maenpaa, H. Korpela, G.A. Kaplan, J. Lynch, S.P. Helmrich and R. Salonen, Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men, Brit. Med. J. 311 (1995), 1124-1127.
51. E.D. Schleicher, E. Wagner and A.G. Nerlich, Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging, J. Clin. Invest. 99 (1997), 457-468.
52. A.M. Schmidt, O. Hori, J. Brett, S.D. Yan, J.L. Wautier and D. Stern, Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions, Arterioscler. Thromb. 14 (1994), 1521-1528.
53. A.M. Schmidt, O. Hori, J.X. Chen, J.F. Li, J. Crandall, J. Zhang, R. Cao, S.D. Yan, J. Brett and D. Stern, Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes, J. Clin. Invest. 96 (1995), 1395-1403.
54. A.M. Schmidt, S.D. Yan and D.M. Stern, The dark side of glucose, Nature Med. 1 (1995), 1002-1004.
55. B.C. Scott, O.I. Aruoma, P.J. Evans, C. O'Neill, A. Van der Vliet, C.E. Cross, H. Tritschler and B. Halliwell, Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation, Free Radic. Res. 20 (1994), 119-133.
56. K. Shikata, H. Makino, H. Sugimoto, M. Kushiro, K. Ota, K. Akiyama, N. Araki, S. Horiuchi and Z. Ota, Localization of advanced glycation endproducts in the kidney of experimental diabetic rats, J. Diabetes Complications 9 (1995), 269-271.
57. C.D. Stehouwer and N.C. Schaper, The pathogenesis of vascular complications of diabetes mellitus: one voice or many?, Eur. J. Clin. Invest. 26 (1996), 535-543.
58. K. Sugimoto, Y. Nishizawa, S. Horiuchi and S. Yagihashi, Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct, Diabetologia 40 (1997), 1380-1387.
59. A.W. Stitt, Y.M. Li, T.A. Gardiner, R. Bucala, D.B. Archer and H. Vlassara, Advanced glycation end products (AGEs) colocalize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats, Am. J. Pathol. 150 (1997), 523-539.
60. R.K. Sundaram, A. Bhaskar, S. Vijayalingam, M. Viswanattham, R. Mohan and K.R. Shanmugasundaram, Antioxidant status and lipid peroxidation in type II diabetes with and without complications, Clin. Sci. Colch. 90 (1996), 255-260.
61. Y.J. Suzuki, M. Tsuchiya and L. Packer, Lipoate prevents glucose-induced protein modifications, Free Radic. Res. Commun. 17 (1992), 211-217.
62. Y.J. Suzuki, M. Tsuchiya and L. Packer, Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species, Free Radic. Res. Commun. 15 (1991), 225-236.
63. B. Tesfamariam, Free radicals in diabetic endothelial cell dysfunction, Free Radic. Biol. Med. 16 (1994), 383-391.
64. J.E. Thompson, R.J. Phillips, H. Erdjument-Bromage, P. Tempst and S. Ghosh, I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B, Cell 80 (1995), 573-582.
65. H. Vlassara, H. Fuh, Z. Makita, S. Krungkrai, A. Cerami and R. Bucala, Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications, Proc. Natl. Acad. Sci. USA 89 (1992), 12043-12047.
66. H. Vlassara, L.J. Striker, S. Teichberg, H. Fuh, Y.M. Li and M. Steffes, Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats, Proc. Natl. Acad. Sci. USA 91 (1994), 11 704-11 708.
67. H. Vlassara, R. Bucala and L. Striker, Pathogenetic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging, Lab. Invest. 70 (1994), 138-151.
68. H. Vlassara, H. Fuh, T. Donnelly and M. Cybulsky, Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits, Mol. Med. 1 (1995), 447-456.
69. H. Vlassara, Advanced glycation end-products and atherosclerosis, Ann. Med. 28 (1996), 419-426.
70. J.L. Wautier, C. Zoukourian, O. Chappey, M.P. Wautier, P.J. Guillausseau, R. Cao, O. Hori, D.M. Stern and A.M. Schmidt, Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats, J. Clin. Invest. 96 (1996), 238-243.
71. B.H. Wolffenbuttel, D. Giordano, H.W. Founds and R. Bucala, Long term assessment of glucose-control by haemoglobin-AGE measurements, Lancet 327 (1996), 513-515.
72. S.D. Yan, A.M. Schmidt, G.M. Anderson, J. Zhang, J. Brett, Y.S. Zhou, D. Pinsky and D.M. Schmidt, Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins, J. Biol. Chem. 269 (1994), 9889-9897.
73. S.D. Yan, S.F. Yan, X. Chen, J. Fu, M. Chen, P. Kuppusamy, M.A. Smith, G. Perry, G.C. Godman, P. Nawroth, J.L. Zweier and D.M. Stern, Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide, Nat. Med. 1 (1995), 693-699.
74. S.D. Yan, D. Stern and A.M. Schmidt, What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose, Eur. J. Clin. Invest. 27 (1997), 179-181.
75. M. Yaqoob, A.W. Patrick, P. McClelland, A. Stevenson, H. Mason, M.C. White and G.M. Bell, Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus, Clin. Sci. Colch. 85 (1993), 557-562.
76. D. Ziegler, M. Hanefeld, K.J. Ruhnau, H.P. Meißner, M. Lobisch, K. Schütte, F.A. Gries and the ALADIN Study Group, Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant lipoic acid. A 3-week multicenter randomized controlled trial (ALADIN Study), Diabetologia 38 (1995), 1425-1433.